> Ranbaxy Laboratories has received FDA approval to market a generic version of GlaxoSmithKline's HIV drug Retrovir. Story
> Brisbane, Ca.-based VaxGen plans to raise $15 million through the sale of part of its interest in the South Korean company Celltrion. Story
> Isotechnika announced that its psoriasis treatment met all primary and secondary endpoints in a Phase III trial. Report
> Shares of Alkermes dropped this morning after the FDA announced a three-month delay in its decision on the alcoholism treatment Vivitrex. The biotech is partnered with Cephalon on the drug. Report
> The FDA has given fast-track status to Medicure's cardioprotective drug, MC-1. Report
> South San Francisco-based CoTherix has filed to sell 4.5 million shares of common stock. Release
> Shares of Gaithersburg, Md.-based GenVec slipped after the company announced plans to sell 7.3 million shares of stock. Story
> Increased competition has forced Alnylam to give up development of its experimental therapy for macular degeneration. Story
> Alexion of Cheshire, Conn. has completed enrollment for a Phase III trial of eculizumab in patients with the chronic orphan blood disorder Paroxysmal Nocturnal Hemoglobinuria. Release
And finally...California's attorney general wants to force companies to add labels that alert consumers to the use of a chemical used in French fries--acrylamide--that causes cancer in lab mice. Article